Answers are grounded in this paper and cite their sources.
Current evidence suggests that tofersen effectively reduces SOD1 and NfL levels and slow disease progression in SOD1 ALS, showing promise as a targeted therapeutic option.
No takes yet. Share an insight, caveat, or question.
Hamad et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: